Mersiha Torlak

Elevated preoperative neutrophil-to-lymphocyte ratio may be associated with decreased overall survival in patients with metastatic clear cell renal cell carcinoma undergoing cytoreductive nephrectomy

Objective Inflammatory serum markers have proven to be a powerful predictive tool of patient prognosis in cancer treatment for a wide variety of solid organ malignancies, predominantly in the context of localized disease. In this study we evaluated the preoperative neutrophil-to-lymphocyte ratio (NLR) as a predictive tool in patients with metastatic clear cell renal cell carcinoma (RCC). Methods Sixty-four patients with metastatic clear cell RCC undergoing nephrectomy were selected. Only patients with preoperative NLR were included for survival analysis. Patients were categorized into high and low NLR score determined by plotting the NLR ROC curve. Multivariable analysis was performed. Results Median age was 60.8 years (38.2–81.2). Median follow-up time was 8.1 months (0.1–106.3). Fuhrman grade distribution was: 2 (3.1%) grade 1, 6 (9.4%) grade 2, 24 (37.5%) grade 3 and 32 (50.0%) grade 4. Median NLR score was 3.5 (1.4–31.0). NLR ≥ 4 was associated with decreased overall survival compared to NLR < 4 (p = 0.017). Multivariable survival analysis showed NLR ≥ 4 as an independent predictor of survival (Hazard ratio (HR) 2.41, 95%CI 1.05–5.50, p = 0.03). Conclusion Elevated preoperative NLR is associated with poor prognosis in patients with metastatic kidney cancer. Preoperative NLR is a useful tool, which can predict prognosis, stratify patients for postoperative surveillance, and help guide decisions for therapy.

Detection of prostate cancer-specific transcripts in extracellular vesicles isolated from post-DRE urine

Background: The measurement of gene expression in post‐digital rectal examination (DRE) urine specimens provides a non‐invasive method to determine a patients risk of prostate cancer. Many currently available assays use whole urine or cell pellets for the analysis of prostate cancer‐associated genes, although the use of extracellular vesicles (EVs) has also recently been of interest. We investigated the expression of prostate‐, kidney‐, and bladder‐specific transcripts and known prostate cancer biomarkers in urine EVs.

MP35-10 DETECTION OF PROSTATE CANCER-ASSOCIATED TRANSCRIPTS IN URINARY EXTRACELLULAR VESICLES

PC 01 28 PC 11 30 PC 01 35 PC 01 16 PC 10 53 PC 10 31 PC 10 08 PC 10 82 PC 11 93 PC 01 34 PC 01 27 PC 01 11 PC 11 67 PC 11 26 PC 01 30 PC 00 46 PC 01 00 PC 01 43 PCA3|PolyA_1.LM2 CXCL14|Reference_end.LM1 SPINK1|Reference_end.LM1 STK36|Reference_end.LM2 ANO7|Reference_end.LM2 TMEM144|Reference_end.LM2 TNFRSF19|Reference_end.LM2 AMACR|PolyA_1.LM2 GPI|PolyA_1.LM2 CAMKK2|Reference_end.LM2 MYBPC1|Reference_end.LM1 EDRF1|Reference_end.LM1 EPCAM|Reference_end.LM2 ANK3|PolyA_1.LM2 SPAG5|Reference_end.LM2 BTG2|Reference_end.LM2 TMEM45B|PolyA_1.LM1 IPO4|Reference_end.LM1 RABGAP1|Reference_end.LM2 ISX|Reference_end.LM2 PSMB2|PolyA_1.LM2 PSMB2|PolyA_1.LM1 SLC25A5|PolyA_1.HE RPL30|Reference_end.HE SOX4|Reference_end.LM1 CLTC|PolyA_2.LM2 DANCR|Reference_end.LM1 SMARCE1|PolyA_1.LM1 −1 −0.5 0 0.5 1 Value 0 60 Color Key and Histogram